Silence Therapeutics Plc (NASDAQ:SLN) stock rose Wednesday after Cantor Fitzgerald initiated coverage with an Overweight rating and a positive outlook for its lead drug candidate.
Cantor Fitzgerald initiated coverage of Silence Therapeutics with an Overweight rating, arguing that the biotech’s lead candidate divesiran could emerge as a major challenger in the polycythemia vera market, with upcoming Phase 2 data expected in August serving as a potentially transformative catalyst and supporting a valuation upside of more than 160%.
Ongoing Phase 2 Study Could Be Major Catalyst
PV is a rare, slow-growing blood cancer that causes the bone marrow to produce too many red blood cells.
SANRECO Phase 2 study evaluating divesiran 6 mg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients is ongoing, with topline results on track for August 2026.
